Fortrea clinical pharmacology services

We believe in being more than a partner

Clinical pharmacology services provide the critical links between preclinical data and new treatments for patients in need. Whether it is your first-in-human study, an exploratory biomarker study, or a study needed for your NDA package, Fortrea scientists and clinicians put principles into action by carefully evaluating drug, safety, tolerability and pharmacokinetics. We provide the answers you need to make the best decisions along your drug development pathway with:

- Integrated services from protocol design to clinical execution and reporting, including biomarkers, bioanalysis and biometrics
- Access to more than 300 beds at four sites across the U.S. and UK, providing multiple options for quality and efficiency
- The only CRO with multiple US sites offering cGMP Phase I manufacturing
- Industry-leading radiolabeled hAME experience, including on-site metabolite ID
- Expertise for special population studies, including renal- and hepatic-impairment

Fortrea

Harnessing technology for human good, together

The industry is changing at an unprecedented pace. You want to leverage technological, medical and scientific innovation to manage complexity. We offer:

- Industry-leading clinical pharmacology experience, with unique enterprise capabilities to bring your compound through preclinical assessment all the way through to commercialization and beyond
- Access to 83K+ healthy volunteers to speed study recruitment
- Experience with 700+ studies in the past five years across therapeutic areas

Leverage Our 25 Years of Global hAME Leadership and Deep Scientific Expertise in Impairment Studies:

- DMPK labs in proximity offering clinics real-time radioanalysis
- More than 90% recovery via LSC on ALL macrotracer hAME studies addressing EMA recommendation
- Over 25 sites in our Phase I impairment site network
- Experience with NASH hepatic Phase I studies

Over **380+** radiolabeled hAME studies

Over **140+** impairment studies including **60** renal and **82** hepatic studies

When one decision can save thousands of lives, your passion becomes our priority

Our 2020-21 pandemic partnership with governments, regulators and customers led to groundbreaking, rapid COVID-19 diagnostic tests and efficient clinical trials, including one for a direct-acting antiviral drug with potent activity against SARS-CoV-2:

- Study setup to first human dose in 23 days
- Sufficient data enabling Phase II submission in 50 days
- 8 SAD, 7 MAD and 1 Food Effect groups, with follow-up completed in 16 weeks

Under standard timelines, Phase II initiation would have taken 33 weeks; study completion would have taken 46 weeks. When every moment counts, count on us to find a way forward.

Consider us your source for powering clear, confident health decisions

We have an entrepreneurial mindset—challenging the status quo, continuously innovating and optimizing operations to create exceptional value for you. We act with urgency, knowing that one day our loved one's care may depend on it. We deliver with purpose, around the clock and around the globe, because that's the best way to help you shape the future of healthcare.

LEARN MORE at fortrea.com

Fortrea